

Cordani David
Form 4
December 26, 2018

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Cordani David

2. Issuer Name and Ticker or Trading Symbol
Cigna Holding Co [CI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
12/20/2018

Director 10% Owner
 Officer (give title below) Other (specify below)

President and CEO

900 COTTAGE GROVE RD

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

BLOOMFIELD, CT 06002

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock, \$.25 Par Value	12/20/2018		D ⁽¹⁾⁽²⁾	305,006	\$ 0 <u>(1)</u> <u>(2)</u> 0	D	
Common Stock, \$.25 Par Value	12/20/2018		D ⁽¹⁾⁽²⁾	1,640.1881 <u>(3)</u>	\$ 0 <u>(1)</u> <u>(2)</u> 0	I	By 401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474 (9-02)

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying Security (Instr. 3 and 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	
Employee Stock Option (Right to Buy)	\$ 42.19	12/20/2018		D	(1)(2)		189,610	(4)	03/01/2021	Common Stock, \$.25 Par Value
Employee Stock Option (Right to Buy)	\$ 44.425	12/20/2018		D	(1)(2)		200,229	(4)	02/28/2022	Common Stock, \$.25 Par Value
Employee Stock Option (Right to Buy)	\$ 58.73	12/20/2018		D	(1)(2)		206,843	(4)	03/05/2023	Common Stock, \$.25 Par Value
Employee Stock Option (Right to Buy)	\$ 78.035	12/20/2018		D	(1)(2)		229,443	(4)	02/26/2024	Common Stock, \$.25 Par Value
Employee Stock Option (Right to Buy)	\$ 120.895	12/20/2018		D	(1)(2)		159,388	(4)	02/25/2025	Common Stock, \$.25 Par Value
Employee Stock Option (Right to Buy)	\$ 139.22	12/20/2018		D	(1)(2)		142,801	(6)	03/01/2026	Common Stock, \$.25 Par Value
Employee Stock Option	\$ 149.135	12/20/2018		D	(1)(2)		119,053	(7)	02/28/2027	Common Stock, \$.25 Par

(Right to Buy)							Value
Employee Stock Option (Right to Buy)	\$ 197.35	12/20/2018	D ⁽¹⁾⁽²⁾	93,490	⁽⁸⁾	02/28/2028	Common Stock, \$.25 Par Value
Phantom Stock Units ⁽⁹⁾	⁽⁹⁾	12/20/2018	D ⁽¹⁾⁽²⁾⁽⁹⁾	3,120.6486	⁽⁹⁾	⁽⁹⁾	Common Stock, \$.25 Par Value

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Cordani David 900 COTTAGE GROVE RD BLOOMFIELD, CT 06002	X		President and CEO	

Signatures

/s/ Amy C. Cook,
attorney-in-fact
Date: 12/26/2018

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)
- (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value \$0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value \$0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was \$193.30.
 - (2) Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.
 - (3) This option was fully vested and exercisable at the time of the Merger.
 - (4) In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.

Edgar Filing: Cordani David - Form 4

(6) Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for \$139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.

(7) One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for \$149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.

(8) This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for \$197.35 per share on the same vesting terms.

(9) The phantom stock units described in Table II are credited under the Cigna Executive Deferred Compensation Plan. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.